Allogeneic Mesenchymal Stromal Cell (MSC) therapy for knee osteoarthritis (OA): A phase I/II randomized controlled trial

      Introduction: OA is the most common joint disease and a leading cause of chronic joint pain and disability. This is particularly apparent at the knee, one of the commonest sites to be affected. Conventional treatments offer modest symptomatic benefits with no evidence of cartilage regeneration. Previous clinical reports, particularly in chondral lesions and partial meniscectomy, have shown feasibility, safety, and structural amelioration both in articular cartilage and meniscus following MSC therapy. This study aimed at assessing the safety and efficacy of an allogeneic cell-therapy based on umbilical cord derived MSC (UC-MSC) 20 × 106 cells (Cellistem-OA®) delivered via intra-articular injection to the affected knee at 12 month of follow-up.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect